Targeting Myeloma Microenvironment as Antitumor Strategy
Nahla A M Hamed*
Internal Medicine Department (Hematology Unit), Faculty of Medicine, Alexandria University, Alexandria, Egypt
Submission: October 04, 2021; Published: October 19, 2021
*Corresponding Address: Nahla A M Hamed, Internal Medicine Department (Hematology Unit), Faculty of Medicine, Alexandria University, Alexandria, Egypt Cancer
How to cite this article: Nahla A M H. Targeting Myeloma Microenvironment as Antitumor Strategy. Canc Therapy & Oncol Int J. 2021; 20(1): 556026. DOI: 10.19080/CTOIJ.2021.20.556026
Abstract
Despite the great advance in myeloma treatment, it still considered a fatal disease due to the permissive role played by the bone marrow (BM) microenvironment in disease establishment and progression. Understanding mechanisms of malignant plasma cells trafficking into and out of the BM may lead to improvement in prevention of disease progression and in overcoming drug resistance. The trafficking and homing of malignant plasma cells to the BM are regulated by soluble factors, and by direct interaction between plasma cells and bone marrow-resident cells. In the BM niche, malignant plasma cells reprogram the local BM microenvironment to induce malignant plasma cells retention, proliferation and drug resistance. Extramedullary disease develops in some patients, as a result of changes in plasma cells chemokine receptor expression or function and their independency of survival factors in BM niche. Furthermore, malignant plasma cells can prepare premetastatic niches for tumor dissemination in distant bone regions, by releasing cytokines, growth factors, and exosomes that remodel the extracellular matrix at these new sites.
Abbreviations: BM: Bone Marrow; BMSC: BM Mesenchymal Stromal Cells; MM: Multiple Myeloma; TME: Tumor Microenvironment; CXCR: Chemokine Receptor; PDE: Phosphodiesterase; VEGF: Vascular Endothelial Growth Factor; SDF: Stromal Cell–Derived Factor; BAFF: B-cell Activating Factor; HSP: Heat-Shock Proteins.
Introduction
Multiple myeloma (MM) is a hematological malignancy characterized by growth and expansion of clonal plasma cells almost exclusively in the bone marrow (BM) [1]. Multipleosteolytic lesions are present in most myeloma patients [2]. These lesions represent osteolytic bone metastasis rather than bone marrow infiltration, as in other hematological malignancies [3]. MM is still a fatal malignancy despite the great advance in its treatment. This is mainly attributed to the permissive role of the BM microenvironment in differentiation, proliferation, migration, survival, and drug resistance of the malignant plasma cells [1].
Malignant plasma cell trafficking and MM development
Malignant plasma cells reach the BM niche through sinusoids, where it proliferates favored by the tumor microenvironment (TME) [2]. The progression and ‘metastasis’ of MM occurs through trafficking of malignant plasma cells continuously in and out of the BM to reach new BM sites [2]. Occasionally, malignant plasma cells egress from the BM to reach different organs causing extramedullary disease [4].
BM Microenvironment
The bone marrow microenvironment is also known as the bone marrow niche. It consists of a cellular and non-cellular component [3]. Each component exerts different effects on malignant plasma cells progression and both components work synergistically [1].
i. The cellular component is subdivided into hematopoietic cells (myeloid-derived suppressor cells, T lymphocytes, B lymphocytes, NK cells, regulatory T cells and osteoclasts) and non-hematopoietic cells (bone marrow stromal cells, fibroblasts, osteoblasts, endothelial cells, and blood vessels) [1].
ii. The non-cellular component includes the extracellular matrix, oxygen concentration, as well as cytokines, growth factors, and chemokines produced and/or affected by the cellular component of the BM microenvironment [1].
Homing
The migration of the malignant plasma cells to specific BM niches, their adhesion to the BM microenvironment, and the egress or mobilization of some of these cells into the peripheral circulation to home to other new BM sites is an active dynamic process. The process of cell migration through the blood to the BM niches is termed homing [2]. Homing and retention of normal and malignant plasma cells into the BM is mainly mediated by the interaction of chemokine receptor CXCR4 on malignant cell surface, with its ligand CXCL12. Other adhesion molecules of importance in mediating malignant plasma cells homing are the α4β7 integrin (MAdCAM-1 and fibronectin receptor), and CD44. The interaction of CXCL12 with CXCR4 upregulates the α4β1 integrin activity, allowing its binding to its ligand VCAM-1 expressed on the BM microvasculature. This event plays key role in malignant plasma cells recirculation. P and E-selectin and their ligands (P-selectin glycoprotein ligand-1, PSGL-1) expressed on the surface of malignant plasma cells also contribute to their attachment to the BM microvasculature [4].
Malignant plasma cells survival and proliferation
CXCL12, along with α4β1, α4β7, and αLβ2 integrins, as well as CD44 are secreted by BM mesenchymal stromal cells (BMSC). Two main soluble mediators of the tumor necrosis factor superfamily contribute to survival and proliferation of malignant plasma cells: a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), which bind to B-cell maturation antigen (BCMA) on the cancer cell surface, and IL-6, whose receptor expressed on MM cells [4].
Educating the BM Niche
Upon MM niche stabilization, malignant plasma cells reprogram the local BM microenvironment, to provide further expansion signals for malignant plasma cells, which gradually become independent from initial normal niche support [4]. These responses occur through direct contact of malignant plasma cells with stromal, endothelial or osteolineage cells, as well as their stimulation by supportive cytokines [4]. This adhesive interaction between malignant plasma cells and marrow cells microenvironment results in secretion of growth and/or antiapoptotic factors including interleukin -6, insulin-like growth factor -1, vascular endothelial growth factor (VEGF), tumor necrosis factor -α, stromal cell–derived factor (SDF) 1α, and B-cell activating factor (BAFF). These factors trigger multiple proliferative/antiapoptotic signaling cascades in malignant plasma cells: Ras/Raf/mitogen-activated protein kinase (MAPK) kinase (MEK)/extracellular signal-related kinase (ERK); Janus kinase (JAK) 2/signal transducers and activators of transcription (STAT)-3; phosphatidylinositide-3 kinase (PI3K)/Akt; nuclear factor (NF)–κB; Wnt and Notch [2].
Extramedullary Disease
In the final phases of the disease, myeloma cells become independent from growth signals provided by the BM milieu and egress of from the BM to the bloodstream to colonize different organs. Malignant plasma cells egress from the BM is induced by decrease in CXCR4 expression and function [4] and by silencing of macrophage migration inhibitory factor (MIF) binding to CXCR4. The chemokine receptor CCR1 expressed on malignant plasma cells and its ligand CCL3 is also associated with increased circulating MM cells [4]. Furthermore, malignant plasma cells can prepare premetastatic niches which attract and maintain tumor dissemination in distant bone regions through release of growth factors, cytokines and exosomes that remodel the extracellular matrix at distant new bone site [4]. For example, bone marrow-derived hematopoietic cells expressing VEGFR1 home to tumor premetastatic sites forming cellular clusters. This process is coincidental with fibronectin upregulation at these sites to provide a permissive niche before tumor cells arrival [1]. Exosomes are a sub‑fraction of extracellular vesicles that are associated with cell-to-cell communication [3]. Exosomes represent a source of long-distance transfer of mRNAs, proteins and growth factors to cell components of the BM microenvironment to alter their phenotype to foster a premetastatic niche suitable for expansion of arriving tumor cells [4].
Potential targets for blocking microenvironmental support of myeloma
Cytokines, cytokines receptors, their downstream protein kinases and transcription factors represent potential targets for blocking myeloma microenvironmental support.
CXCR4 inhibitor
Plerixafor (AMD3100) is a CXCR4 inhibitor that blocks CXCL12– CXCR4 interaction. This disrupts malignant plasma cells contact with the BM microenvironment and allows their mobilization into the circulation [4]. AMD3100 enhance the in vitro sensitivity to bortezomib by disrupting adhesion of malignant plasma cells to stromal cells. The combination of AMD3100 and bortezomib increased the ratio of apoptotic circulating cells compared to bortezomib-treated groups [2].
· G-CSF or cyclophosphamide infusion in MM stem cell transplant patients disrupts the SDF-1/CXCR4 axis. This will decrease endogenous SDF-1 concentration in BM and will enhance mobilization or egress of cells outside the BM [2].
hsp90 Inhibitor
hsp90 inhibition will suppress cell surface expression of insulin-like growth factor–1R and interleukin-6R, as well as expression and/or function of Akt, Raf, IKK-α, and p70S6K. These will decrease the amplitude of signaling via the PI3K/Akt/mTOR, Ras/Raf/MAPK, and IKK/NF-κB pathways, leading to diverse downstream proapoptotic molecular changes [2].
Phosphodiesterase-5 (PDE5) Inhibitor
E.g. tadalafil: it reduced MDSC function in relapsed/ refractory MM patients [5]. PDE5 inhibitors downregulate arginase 1 and nitric oxide synthase-2 expression and reduce the suppressive machinery of tumor recruited MDSCs in murine tumor models [1].
Conclusion
The clinical behavior of multiple myeloma depends not only on the genetic changes in tumor cells but also on their interaction with the microenvironment. Elucidation of the molecular mechanisms of MM niche are required to determine novel target approaches of beneficial effects on MM tumor progression and drug resistance.
References
- Freddie B, Jacques F, Isabelle S, Rebecca S, Lindsey T, et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6): 394-424.
- Sher T, Dy GK, Adjei AA (2008) Small cell lung cancer. Mayo Clin Proc 83(3): 355–367.
- Van Meerbeeck JP, Fennell DA, De Ruysscher DK (2011) Small-cell lung cancer. Lancet 378(9804): 1741–1755.
- Kalemkerian GP (2012) Staging and imaging of small cell lung cancer. Cancer Imaging 11(1): 253-258.
- James R Jett, Schild SE, Kesler KA, Kalemkerian GP (2013) Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd edn: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl): e400S–e419S.
- Dingemans AC, Fruh M, Ardizzoni A, B Besse, C Faivre-Finn, et al. (2021) Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(7): 839-853.
- El Maalouf G, Rodier J-M, Faivre S, Eric Raymond (2007) Could we expect to improve survival in small cell lung cancer? Lung Cancer 57 Suppl 2: S30–S34.
- Noda K, Nishiwaki Y, Kawahara M, Shunichi Negoro, Takahiko Sugiura, et al. (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346(2): 85–91.
- Lally BE, Geiger AM, Urbanic JJ, Jerome M Butler, Stacy Wentworth, et al. (2009) Trends in the outcomes for patients with limited stage small cell lung cancer: an analysis of the surveillance, epidemiology, and end results database. Lung Cancer 64(2): 226–231.
- Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, et al. (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357: 664-672.
- Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavljevic S, et al. (1999) Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. J Clin Oncol 17(7): 2092-2099.
- Slotman BJ, van Tinteren H, Praag JO, Joost L Knegjens , Sherif Y El Sharouni, et al. (2015) Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 385(9962): 36–42.
- Slotman BJ, Faivre-Finn C, van Tinteren H, Keijser A, Praag J, et al. (2017) Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: a secondary analysis of the Phase III CREST trial. Lung Cancer 108: 150–153.
- Palma DA, Warner A, Louie AV, Senan S, Slotman B, et al. (2016) Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis. Clin Lung Cancer 17(4): 239-244.
- Yee D, Butts C, Reiman A, Joy A, Smylie M, et al. (2012) Clinical trial of post chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer. Radiother Oncol 102(2): 234-238.
- Zhu H, Zhou Z, Wang Y, Bi N, Feng Q, et al. (2011) Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis. Cancer 117(23): 5423-5431.
- Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, et al. (2017) Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG oncology RTOG 0937. J Thorac Oncol 12: 1561–1270.
- Palma DA, Senan S, Oberije C, Belderbos J, de Dios NR, et al. (2013) Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 87(4): 690-696.
- Yoon HG, Noh JM, Ahn YC, Oh D, Pyo H, et al. (2019) Higher thoracic radiation dose is beneficial in patients with extensive small cell lung cancer. Radiat Oncol J 37(3): 185–192.
- Li-Ming X, Zhao L-J, Simone CB, Cheng C, Kang M, et al. (2017) Receipt of thoracic radiation therapy and radiotherapy dose are correlated with outcomes in a retrospective study of three hundred and six patients with extensive stage small-cell lung cancer. Radiother Oncol 125(2): 331–337.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Small Cell Lung Cancer Version 2.2020 (2020) National Comprehensive cancer Network.
- Hochstenbag MM, Twijnstra A, Wilmink JT, E F Wouters, G P ten Velde (2000) Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol 48(3): 243-248.
- Arriagada R, Le Chevalier T, Borie F, A Riviere, P Chomy, et al. (1995) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 87(3): 183-190.
- Jeremic B, Gomez-Caamano A, Dubinsky P, Cihoric N, Casas F, et al. (2017) Radiation therapy in extensive stage small cell lung cancer. Front Oncol 7: 169.
- Auperin A, Arriagada R, Pignon JP, C Le Pechoux, A Gregor, et al. (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341(7): 476-484.
- Slotman B, Faivre-Finn C, Kramer G, Elaine Rankin, Michael Snee, et al. (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357: 664-672.
- Takahashi T, Yamanaka T, Seto T, Hideyuki Harada, Hiroshi Nokihara, et al. (2017) Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 18(5): 663-671.
- Le Pechoux C, Laplanche A, Faivre-Finn C, T Ciuleanu , R Wanders et al. (2011) Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol 22(5): 1154-1163.
- Wolfson AH, Bae K, Komaki R, Christina Meyers, Benjamin Movsas, et al. (2011) Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 81(1): 77-84.
- Paz-Ares L, Dvorkin M, Chen Y, Niels Reinmuth , Katsuyuki Hotta, et al. (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212): 1929-1939.
- Horn L, Mansfield AS, Szczęsna A, Libor Havel, Maciej Krzakowski, et al. (2018) First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 379(23): 2220-2229.
- Antonia SJ, Villegas A, Daniel D, David Vicente , Shuji Murakami, et al. (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379(24): 2342-2350.
- Antonia SJ, Villegas A, Daniel D, David Vicente, Shuji Murakami, et al. (2017) Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med 377: 1919-1929.
- Formenti SC, Rudqvist NP, Golden E, Benjamin Cooper , Erik Wennerberg, et al. (2018) Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 24(12): 1845-1851.
- Demaria S, Ng B, Devitt ML, James S Babb, Noriko Kawashima, et al. (2004) Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58(3): 862-870.
- Golden EB, Chhabra A, Chachoua A, Sylvia Adams , Martin Donach, et al. (2015) Local radiotherapy and granulocyte-macrophage colony stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol 16(7): 795-803.
- Deng L, Liang H, Burnette B, Michael Beckett, Thomas Darga, et al. (2014) Irradiation and anti PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124(2): 687-695.
- Dovedi SJ, Cheadle EJ, Popple AL, Edmund Poon, Michelle Morrow, et al. (2017) Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade. Clin Cancer Res 23(18): 5514-5526.
- Postow MA, Callahan MK, Barker CA, Yoshiya Yamada, Jianda Yuan, et al. (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366: 925-931.
- Tawbi HA, Forsyth PA, Algazi A, Omid Hamid, F Stephen Hodi, et al. (2018) Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med 379(8): 722-730.
- Xu LM, Cheng C, Kang M, Jing Luo, Lin Lin Gong, et al. (2017) Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer. Sci Rep 7(1): 9255.